酰胺质子转移加权MRI测量在胶质瘤患者中获得一致且可重复的结果:一项前瞻性重测研究
前瞻性重测研究纳入52名健康志愿者和52例组织学确诊胶质瘤患者,间隔1分钟连续行两次3-T MRI,用含/不含流体抑制两种模型重建酰胺和胺质子转移加权信号,ICC和Bland-Altman显示患者各肿瘤区域一致性优秀(ICC=0.76-0.89),对比增强肿瘤最高。
要点
- 胶质瘤患者酰胺/胺质子转移加权测量重测一致性优秀(ICC=0.76-0.89),对比增强肿瘤区最高。
- 健康志愿者一致性中等至优秀(ICC=0.53-0.74),酰胺质子转移加权最高(ICC=0.73-0.74)。
- 流体抑制显著影响信号强度分布(各VOI p<0.001),Bland-Altman示系统偏倚可忽略且无比例偏倚。
核心结论
- 酰胺/胺质子转移加权成像在胶质瘤患者中获得一致且可重复的测量结果,这是神经肿瘤学中稳健影像生物标志物发现的前提。
研究设计与样本
- 前瞻性重测研究,纳入52名健康志愿者和52例组织学确诊胶质瘤患者,间隔1分钟连续行两次3-T MRI,CEST测量用含和不含流体抑制两种模型重建,评估酰胺和胺偏移。
关键影像表现/征象
- 酰胺/胺质子转移加权信号强度分布显著受流体抑制影响,各VOI的p<0.001。
- 健康志愿者中酰胺质子转移加权信号强度值最高,ICC=0.73-0.74。
诊断标准与关键数值
- 健康志愿者重测一致性中等至优秀,ICC=0.53-0.74,酰胺质子转移加权最高(ICC=0.73-0.74)。
- 胶质瘤患者各肿瘤区域酰胺和胺质子转移加权测量一致性优秀,ICC=0.76-0.89,对比增强肿瘤测量ICC最高。
- Bland-Altman分析示系统偏倚可忽略,测量误差无比例偏倚。
临床应用与阅片要点
- 在胶质瘤患者中,酰胺/胺质子转移加权测量在不同肿瘤区域(对比增强、非增强、全肿瘤及正常表现白质)均显示优秀重测一致性,尤以对比增强肿瘤区最高。
- 流体抑制与否显著影响信号强度分布,解读酰胺/胺质子转移加权信号时需明确重建模型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Chemical exchange saturation transfer (CEST) imaging has emerged as a promising imaging biomarker, but its reliability for clinical practice remains uncertain. This study aimed to investigate the robustness of CEST parameters in healthy volunteers and patients with brain tumours.
METHODS: A total of n = 52 healthy volunteers and n = 52 patients with histologically confirmed glioma underwent two consecutive 3-T MRI scans separated by a 1-min break. The CEST measurements were reconstructed using two models: with and without fluid suppression and included the evaluation of both amide (amidePTw) and amine (aminePTw) offsets. Mean intensity values in healthy volunteers were compared from volumetric segmentations (VOI) of grey matter, white matter, and the whole brain. Mean intensity values in brain tumour patients were assessed from VOI of the contrast-enhancing, non-enhancing and whole tumour, as well as from the normal-appearing white matter. Test-retest reliability was assessed using ICC and Bland-Altman plots.
RESULTS: The amidePTw/aminePTw signal intensity distribution was significantly affected by fluid suppression (p < 0.001 for each VOI). Test-retest reliability in healthy volunteers showed fair to excellent agreement (ICC = 0.53-0.74), with the highest signal intensity values observed by amidePTw (ICC = 0.73-0.74). In patients, an excellent agreement of both amidePTw and aminePTw measurements was observed across different tumour regions (ICC = 0.76-0.89), with the highest ICC for contrast-enhancing tumour measurements. Bland-Altman analysis indicated negligible systematic bias and no proportional bias in measurement errors.
CONCLUSION: Measurements from amide/aminePTw imaging obtained from an adequately powered test-retest study yield consistent and reproducible results in glioma patients, as a prerequisite for robust imaging biomarker discovery in neuro-oncology.
KEY POINTS: Question The clinical reliability of chemical exchange saturation transfer imaging remains uncertain, necessitating further investigation to establish its robustness as a biomarker in neuro-oncology. Findings This study demonstrates that amide/amine proton transfer imaging provides repeatable, high-agreement measurements in glioma patients, particularly in contrast-enhancing tumour regions. Clinical relevance This test-retest study demonstrates that chemical exchange saturation transfer imaging using two models and assessing amide and amine offsets yield consistent and repeatable results in glioma patients, as a prerequisite for robust imaging biomarker discovery for neuro-oncology studies and clinical practice.
引用
- Pflüger I, Rastogi A, Casagranda S, et al. Amide proton transfer weighted MRI measurements yield consistent and repeatable results in patients with gliomas: a prospective test-retest study. Eur Radiol. 2024. PMID: 39694884. doi:10.1007/s00330-024-11197-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。